Clinical trials: Leptomeningeal Neoplasms
Leptomeningeal Metastasis, Durvalumab
Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
The purpose of this study is to observe the clinical efficacy and safety of Durvalumab combined with intrathecal chemotherapy in non-small cell lung cancer with leptomeningeal metastasis
- Trial name
- NCT04356222
- Testing
- Durvalumab, methotrexate
- Volunteers
- 30 people
- Sponsor
- Hui Bu
Neoplastic Meningitis, Solid Tumor
RTA 744 Injection in Patients With Leptomeningeal Disease
1. The primary objectives of this study are: 1. To determine the tolerability of RTA 744 Injection in patients with leptomeningeal disease (LMD) secondary to any type of primary tumor. 2.
- Conditions
- Neoplastic Meningitis, Solid Tumor, Lymphoma, Leukemia
- Trial name
- NCT00512460
- Testing
- RTA 744
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
NSCLC, Low Dose Radiotherapy
Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer
This phase I study aims to investigate the safety and efficacy of whole brain low dose radiotherapy (WB-LDRT) combined with ICI and intrathecal chemotherapy for treatment of refractory meningeal metastasis of lung cancer.
- Conditions
- NSCLC, Low Dose Radiotherapy, PD-1 Inhibitor, Leptomeningeal Metastasis
- Trial name
- NCT06431685
- Testing
- Whole Brain Low Dose Radiotherapy, Pemetrexed, Sintilimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sichuan University
Ependymoma, Glioblastoma
Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma
This phase I trial investigates the side effects of brain tumor-specific immune cells (IL13Ralpha2-CAR T cells) in treating patients with leptomeningeal disease from glioblastoma, ependymoma, or medulloblastoma.
- Conditions
- Ependymoma, Glioblastoma, Medulloblastoma, Recurrent Metastatic Malignant Neoplasm in the Leptomeninges
- Trial name
- NCT04661384
- Testing
- IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma
Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. This phase II trial is studying how well topotecan hydrochloride works in treating children with meningeal cancer that…
- Conditions
- AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma
- Trial name
- NCT00005811
- Testing
- topotecan hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- National Cancer Institute (NCI)
Leptomeningeal Metastasis From Lung Cancer
Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung Adenocarcinoma
The goal of this clinical trial is to learn whether amivantamab combined with intrathecal pemetrexed is safe and may help treat leptomeningeal metastasis in adults with EGFR-mutant lung adenocarcinoma.
- Trial name
- NCT07744529
- Testing
- Amivantamab+ systemic/ intrathecal Pemetrexed
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Solid Tumor, Solid Tumor, Adult
Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
The purpose of this research is to examine if an experimental drug combination impacts the survival rate of individuals with Leptomeningeal Metastases This research study involves an experimental drug combination.
- Conditions
- Solid Tumor, Solid Tumor, Adult, Leptomeningeal Metastasis
- Trial name
- NCT04729348
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Non-small Cell Lung Cancer, Leptomeningeal Metastasis
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
The primary objective of this clinical study is to evaluate the efficacy of high-dose furmonertinib combined with bevacizumab and pemetrexed (triple therapy) in the treatment of non-small cell lung cancer (NSCLC) with…
- Conditions
- Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation
- Trial name
- NCT06643000
- Testing
- furmonertinib
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
This phase II clinical trial studies how well craniospinal irradiation (CSI) with hippocampal avoidance, using proton therapy or volumetric modulated arc therapy (VMAT), works in treating patients with breast cancer or non-small…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Leptomeninges
- Trial name
- NCT06518057
- Testing
- Biospecimen Collection, Computed Tomography, Electronic Health Record Review
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Leptomeningeal Metastasis, Non-small Cell Lung Cancer
Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer
Leptomeningeal metastasis (LM) is a fatal complication of advanced non-small cell lung cancer (NSCLC) associated with poor prognosis and rapid deterioration of performance status.
- Conditions
- Leptomeningeal Metastasis, Non-small Cell Lung Cancer, EGFR Activating Mutation
- Trial name
- OWBLM (NCT04425681)
- Testing
- Osimertinib, Bevacizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Leptomeningeal Metastases, Leptomeningeal Disease
Avelumab With Radiotherapy in Patients With Leptomeningeal Disease
This study is to find a safe dose of the combination of Avelumab and Whole Brain Radiotherapy (WBRT) in patients with Leptomeningeal Disease.
- Trial name
- NCT03719768
- Testing
- Avelumab, Whole Brain Radiotherapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary
Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma
- Trial name
- NCT00112619
- Testing
- topotecan hydrochloride
- Where
- 11 sites in United States
- Volunteers
- 19 people
- Sponsor
- Pediatric Brain Tumor Consortium
Leptomeningeal Disease
Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)
To determine the safety of intrathecal (IT) PD1 antibody for Intrathecal application of PD1 antibody in metastatic solid tumors with leptomeningeal disease of solid tumors.
- Trial name
- IT-PD1 (NCT05112549)
- Testing
- Nivolumab [Opdivo]
- Where
- 9 sites in Germany
- Volunteers
- 46 people
- Sponsor
- University Hospital Tuebingen
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the safety of delivering intrathecal busulfan in children and adolescents who…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Leukemia, Lymphoma
- Trial name
- NCT00006246
- Testing
- busulfan
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Pediatric Brain Tumor Consortium
Metastatic Breast Cancer, Leptomeningeal Disease
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
This study is a prospective evaluation of systemic, intravenous high-dose methotrexate (HD-MTX, 8 g/m2) in patients with triple negative, HER2-positive, and hormone refractory breast cancer with leptomeningeal metastasis (LMD)…
- Trial name
- NCT02422641
- Testing
- High-dose Methotrexate (8 gm/m2; HD-MTX)
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
NSCLC (Advanced Non-small Cell Lung Cancer), Leptomeningeal Metastasis
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
The goal of this clinical trial is to clarify the efficacy and safety of the high-dose alternate-day furmonertinib in NSCLC with leptomeningeal metastasis.
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), Leptomeningeal Metastasis, Furmonertinib, EGFR Activating Mutation
- Trial name
- NCT07348965
- Testing
- Furmonertinib 320mg qod po, Furmonertinib 160mg qd po
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
This phase I trial studies the side effects and best dose of HER2-CAR T cells in treating patients with cancer that has spread to the brain or leptomeninges and has come back (recurrent).
- Conditions
- Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges, Breast Cancer
- Trial name
- NCT03696030
- Testing
- Chimeric Antigen Receptor T-Cell Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- City of Hope Medical Center
Acral Lentiginous Melanoma, Central Nervous System Melanoma
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
This phase I/Ib trial studies the side effects and best dose of intrathecal nivolumab, and how well it works in combination with intravenous nivolumab in treating patients with leptomeningeal disease.
- Conditions
- Acral Lentiginous Melanoma, Central Nervous System Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Leptomeningeal Neoplasm
- Trial name
- NCT03025256
- Testing
- Biospecimen Collection, Computed Tomography, Lumbar Puncture
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Non-Small-Cell Lung, Brain Metastases
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
This study is an investigator-initiated, prospective, open-label, single-arm, multicenter clinical trial aimed at exploring the antitumor activity of Lorlatinib in ALK-positive NSCLC patients with brain/ leptomeningeal metastases.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- NCT06282874
- Testing
- Lorlatinib
- Where
- 3 sites in China
- Volunteers
- 41 people
- Sponsor
- Guangdong Association of Clinical Trials